Case Reports in Psychiatry

Volume 2014 (2014), Article ID 842349, 4 pages

http://dx.doi.org/10.1155/2014/842349

Case Report

31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic Testing Was Used to Inform Treatment

Scott Lawrence

Centerstone, 1080 Ala Napunani Street No. 120, Honolulu, HI 96818, USA

Received 8 January 2014; Accepted 28 January 2014; Published 18 March 2014

Academic Editors: V. Arolt, J. S. Brar, L. Dell’Osso, and F. Oyebode

Copyright © 2014 Scott Lawrence. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

This case describes a 31-year-old female Caucasian patient with complaints of ongoing depression, agitation, and severe panic attacks. The patient was untreated until a recent unsuccessful trial of citalopram followed by venlafaxine which produced a partial response. Genetic testing was performed to assist in treatment decisions and revealed the patient to be heterozygous for polymorphisms in 5HT2C, ANK3, and MTHFR and homozygous for a polymorphism in SLC6A4 and the low activity (Met/Met) COMT allele. In response to genetic results and clinical presentation, venlafaxine was maintained and lamotrigine was added leading to remission of agitation and depression.

1. Introduction

Patient treatment has traditionally been applied in a “one-size fits all” fashion. Most prescriptions have been standardized to target a particular illness or symptom which allows for minimal interindividual variation in treatment response. This becomes critical when treating psychiatric illnesses, as many prescribed medications are not effective in certain individuals or can have serious adverse effects. Information gathered from genetic testing can allow clinicians to predict a patient’s propensity for medication response and risk for adverse drug reactions. Utilizing this information, a treatment plan can be customized to the patient to improve treatment outcomes [1].

2. Case

The patient, a 31-year-old female Caucasian with a long history of depression starting in her early teens, presented to a psychiatric nurse practitioner (PNP) with a chief complaint of incessant crying and worsening agitation. She reported symptoms of severe anergia, slow thought processes, short-term memory problems, and forgetfulness, all of which impacted daily activities, but she denied sleep disturbances. She reported multiple crying spells daily and admitted ongoing isolative behaviors. She also reported agitation leading to daily panic attacks but displayed no manic symptoms or psychosis. Her depression began in her midteens with progressively worsening of symptoms since that time.

The patient’s psychiatric symptoms were managed solely by her primary care physician (PCP) who referred her to a PNP several times over the course of a year before the patient finally consented to be seen by a specialist. Although no official diagnosis was made prior to this visit, after seeing the PNP, she was diagnosed with major depressive disorder, recurrent and moderate (ICD-9 296.32/ICD-10 F33.1), with no presenting comorbidities. She has had no previous outpatient or inpatient treatment and denied suicidal ideation (SI) or attempts. The patient reported no significant medical history. Her family history is significant for unknown psychiatric treatment in her paternal grandmother, aunt, nephew, and brother. These family members were all psychiatrically hospitalized at least once for depression and another brother was diagnosed and treated for anxiety. The patient has two children from her previous marriage and is currently single after her divorce at age 28. Her depression symptoms have led to discussions with her employer about poor performance.

The patient was initiated on citalopram 20 mg by her PCP in January 2012 which was administered for one month but was reported to be entirely ineffective. The patient reports no other medication history. More recently, in March 2012, the patient was initiated on venlafaxine XR by the PNP and, after titration to 300 mg, produced a reduction in crying spells, depression, anxiety, and irritability. However, her symptoms still remained problematic and complaints of anergia and cognitive deficits were ongoing. Genetic testing was performed using the Genecept Assay in May 2012 to further guide treatment decisions. The Genecept Assay, designed by Genomind, LLC (Chalfont, PA), is a saliva based test which analyzes variations in ten genes associated with varied treatment response, treatment efficacy, side effect risk, and drug metabolism. The genes tested are summarized in Table 1. Genetic testing revealed the patient to be heterozygous for the variants rs3813929 of 5HT2C, rs10994336 of ANK3, and rs1801133 of MTHFR and homozygous for the variants rs63749047 of SLC6A4 and low activity allele of COMT.

Table 1: Genes tested using the Genecept Assay.

Gene
Variant
Functional significance

Serotonin transporter (SLC6A4)
Long/short (rs63749047)
Reduced serotonin reuptake

A > G (rs25531)

Serotonin receptor subtype 2C (5HT2C)
−759 C > T (rs3813929)
Altered satiety signaling

Dopamine receptor subtype 2 (DRD2)
141 C INS/DEL (rs1799732)
Altered binding of dopamine and antipsychotics

Voltage-dependent calcium channel L-type, alpha 1c subunit (CACNA1C)
G > A (rs1006737)
Altered neuronal depolarization

Ankyrin G (ANK3)
C > T (rs10994336)
Dysregulation of sodium channels

Catechol-O-methyltransferase (COMT)
158 Val > Met (rs4680)
Altered dopamine degradation

Methylenetetrahydrofolate reductase (MTHFR)
677 C > T (rs1801133)
Impaired folic acid metabolism

Cytochrome P450 2D6 (CYP2D6)
Multiple variations
Variants can lead to poor metabolism, intermediate metabolism, or ultra- metabolism of certain medications

Cytochrome P450 2C19 (CYP2C19)
Multiple variations
Variants can lead to poor metabolism, intermediate metabolism, or ultra- metabolism of certain medications

Cytochrome P450 3A4/5 (CYP3A4/5)
Multiple variations
Increased metabolism of certain medications

3. Discussion

Genotyping for SLC6A4 revealed the patient to be at an increased risk for failure and/or intolerability with SSRI medications. Serotonin is removed from the synapse and returned to presynaptic cells by the serotonin transporter protein [2]. Variants in this gene result in altered transcription and consequently reduced levels of serotonin reuptake [3]. Several large meta-analyses have shown that the S allele correlates with slow response, poor response, and greater risk of side effects to selective serotonin reuptake inhibitors (SSRIs) [4, 5]. The mechanism of action of an SSRI selectively targets the serotonin transporter protein [6], and the presence of this variation may provide a potential explanation for the patient’s failure with the SSRI citalopram. The patient’s SSRI treatment history is limited, however, making it difficult to identify the exact cause of citalopram failure. Pharmacological agents that do not primarily target the serotonin transporter protein may be advantageous in patients who display this variation. Although the SLC6A4 variation may impact the serotonin pathway activity of venlafaxine, a commonly prescribed SNRI, the patient’s partial response to this agent may be explained by its additional effects on the norepinephrine pathway. The decision to maintain venlafaxine was made with the patient reporting continued improvements in depression, anxiety, and irritability, as well as reductions in fatigue, better motivation, and some improvement to concentration and focus. Her children also noted that she seemed to be happier.

5HT2C is a site of antagonism by various neuroleptics. Serotonin signals satiety through this receptor [7]. Antagonism of 5HT2C has been shown to lead to increased food intake, hyperlipidemia, glucose intolerance, and obesity [8, 9]. The C allele of the-759C/T polymorphism confers risk for weight gain and metabolic syndrome, while the T allele exhibits protective effects for weight gain in patients taking atypical antipsychotics [9–11]. This patient is heterozygous for the C (high risk) allele and if atypical antipsychotics were a chosen intervention, additional vigilance may be appropriate to avoid and monitor weight gain.

The ANK3 gene encodes for a protein crucial to the function of sodium ion channels, and variations in this gene may impact sodium channel activity [12]. The role of ANK3 in the brain includes the mediation of action potential firing and propagation and the modulation of neuronal excitability [12]. Altered ANK3 function could result in disruption of the proper development and function of neural circuits in the brain which regulate mood [12]. There have been numerous large genome-wide association studies that have found single nucleotide polymorphisms (SNPs) in ANK3, including rs10994336, to be correlated with, although not diagnostic for, bipolar disorder, cyclothymic mood disorders, and schizophrenia [13, 14]. SNPs in ANK3 have also been found to be associated with the predisposition of anhedonia, altered novelty seeking, impaired threat and stress signal processing, poorer cognition, and reduced integrity of white matter tracts [12]. The SNP, rs10994336, has not been demonstrated to have a direct impact on gene function; however, it serves as a true marker for another SNP, likely located nearby, which contributes to functional and structural changes in the brain related to symptomatology and risk for bipolar disorder [12]. Mood stabilizing agents, such as lamotrigine, which reduce neuronal excitability, may potentially be beneficial in patients with ion channel variations. Lamotrigine may affect the regulation of neurotransmission and action potential firing via the modulation of ion channel functioning [15]. Lamotrigine has long been used to successfully treat symptoms typically associated with bipolar disorder [15]. Lamotrigine was added as a therapeutic option to combat the patient’s cognitive deficits and ongoing agitation and stress; it was chosen for its mechanism involving sodium channels as a potential modifier of the patient’s ANK3 variation.

COMT is an enzyme responsible for breakdown of dopamine in the frontal lobes of the brain. Dopamine levels in this brain region are critical for memory, attention, judgment, and other executive functions [16, 17]. The literature suggests that this low activity variant may result in reduced dopamine degradation [18] leading to a hyperdopaminergic state and altered stress response [19]. As the patient’s depression symptoms were improved with venlafaxine and lamotrigine was chosen to target the remaining symptoms, no treatments were chosen to target this variation at this time.

Methylfolate is the metabolically active form of folic acid and is essential in the catalytic reactions that produce the monoamine neurotransmitters norepinephrine, dopamine, and serotonin. Methylfolate is formed from folic acid through enzymatic conversion via MTHFR [20]. The risk allele of MTHFR leads to reduced thermodynamic stability and enzymatic activity [21, 22]. Augmentation with L-methylfolate has been demonstrated to produce benefits in several preliminary studies for patients with major depressive disorder [23]. As this patient was found to carry a risk allele in MTHFR, L-methylfolate 15 mg was initiated in June 2012 but was discontinued after one month due to fractional symptom reduction and a high copay cost.

4. Outcome

After the addition of lamotrigine to the patient’s treatment regime, the patient reported continued improvements in depression, anxiety, and mood lability. Low energy, cognitive impairments, and panic attacks also resolved. Additionally, although she had not previously admitted to paranoia in her clinical interviews, she reports that paranoia improved as well. The patient’s response to the new medications was discussed at a follow-up appointment where she indicated a slight return of irritability. Lamotrigine was increased from 100 mg once a day in the morning (qam) to 200 mg qam to target the irritability. The depression and anxiety symptoms were well managed and the venlafaxine dosage was maintained at 300 mg qam. At the most recent follow-up appointment, the patient reported that all symptoms have resolved and she is doing well at her job with no more complaints about her performance. The patient self-initiated a medication washout period against clinical advice to determine if symptomology had resolved on its own, and within two weeks, symptoms had returned. She has since restarted these medications and has been stable with symptoms remaining in remission since returning to the previously achieved doses. Genetic testing proved to be a valuable clinical tool for this patient, guiding medication choices that dramatically impacted underlying symptomatology.

Disclosure

Scott Lawrence is a preferred provider of the Genecept Assay and did receive editorial assistance from Genomind in the writing process.

Conflict of Interests

The author declares that there is no conflict of interests regarding the publication of this paper.

References

K. Evers, “Personalized medicine in psychiatry: ethical challenges and opportunities,” Dialogues in Clinical Neuroscience, vol. 11, no. 4, pp. 427–434, 2009.

P. Schloss and D. C. Williams, “The serotonin transporter: a primary target for antidepressant drugs,” Journal of Psychopharmacology, vol. 12, no. 2, pp. 115–121, 1998.

A. Heils, A. Teufel, S. Petri et al., “Allelic variation of human serotonin transporter gene expression,” Journal of Neurochemistry, vol. 66, no. 6, pp. 2621–2624, 1996.

S. Porcelli, C. Fabbri, and A. Serretti, “Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy,” European Neuropsychopharmacology, vol. 22, no. 4, pp. 239–258, 2012.

M. Kato and A. Serretti, “Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder,” Molecular Psychiatry, vol. 15, no. 5, pp. 473–500, 2010.

K. Hodgson, S. J. Mufti, R. Uher, and P. McGuffin, “Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response,” Genome Medicine, vol. 4, article 52, 2012.

J. C. G. Halford and J. A. Harrold, “5-HT2C receptor agonists and the control of appetite,” Handbook of Experimental Pharmacology, vol. 209, pp. 349–356, 2012.

D. W. Bonhaus, K. K. Weinhardt, M. Taylor et al., “RS-102221: a novel high affinity and selective, 5-HT(2C) receptor antagonist,” Neuropharmacology, vol. 36, no. 4-5, pp. 621–629, 1997.

G. P. Reynolds, Z.-J. Zhang, and X.-B. Zhang, “Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism,” The Lancet, vol. 359, no. 9323, pp. 2086–2087, 2002.

D. D. Miller, V. L. Ellingrod, T. L. Holman, P. F. Buckley, and S. Arndt, “Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism,” American Journal of Medical Genetics: Neuropsychiatric Genetics, vol. 133, no. 1, pp. 97–100, 2005.

P. R. Buckland, B. Hoogendoorn, C. A. Guy, S. K. Smith, S. L. Coleman, and M. C. O'Donovan, “Low gene expression conferred by association of an allele of the 5-HT 2C receptor gene with antipsychotic-induced weight gain,” American Journal of Psychiatry, vol. 162, no. 3, pp. 613–615, 2005.

M. P. Leussis, J. M. Madison, and T. L. Petryshen, “Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology,” Biology of Mood & Anxiety Disorders, vol. 2, no. 1, article 18, 2012.

T. G. Schulze, S. D. Detera-Wadleigh, N. Akula et al., “Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder,” Molecular Psychiatry, vol. 14, no. 5, pp. 487–491, 2009.

M. A. R. Ferreira, M. C. O’Donovan, Y. A. Meng, et al., “Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder,” Nature Genetics, vol. 40, no. 9, pp. 1056–1058, 2008.

J. T. Judy and P. P. Zandi, “A review of potassium channels in bipolar disorder,” Frontiers in Genetics, vol. 4, article 105, 2013.

M. J. Frank and J. A. Fossella, “Neurogenetics and pharmacology of learning, motivation, and cognition,” Neuropsychopharmacology, vol. 36, no. 1, pp. 133–152, 2011.

T. E. Goldberg, M. F. Egan, T. Gscheidle et al., “Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia,” Archives of General Psychiatry, vol. 60, no. 9, pp. 889–896, 2003.

J. Chen, B. K. Lipska, N. Halim, et al., “Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain,” American Journal of Human Genetics, vol. 75, no. 5, pp. 807–821, 2004.

D. Hernaus, D. Collip, J. Lataster, et al., “COMT val(158)met genotype selectively alters prefrontal [(18)F]fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge,” PLoS ONE, vol. 8, no. 6, Article ID e65662, 2013.

D. S. Robinson, “Vitamins, monoamines, and depression,” Primary Psychiatry, vol. 16, no. 2, pp. 19–21, 2009.

S. J. Lewis, D. A. Lawlor, G. Davey Smith et al., “The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis,” Molecular Psychiatry, vol. 11, no. 4, pp. 352–360, 2006.

O. L. J. Peerbooms, J. van Os, M. Drukker et al., “Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability?” Brain, Behavior, and Immunity, vol. 25, no. 8, pp. 1530–1543, 2011.

L. D. Ginsberg, A. Y. Oubre, and Y. A. Daoud, “L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode,” Innovovations in Clinical Neuroscience, vol. 8, no. 1, pp. 19–28, 2011.